A new consumer data set projects that Canadian cannabis consumers will spend over C$1,600 a year on cannabis products by 2025.

On Tuesday (March 26), research and business firm EY announced that the average Canadian cannabis consumer’s spending on cannabis products will increase 30 percent by 2025.


The study is projecting an increase from C$1,263 annually from consumers in 2019 to C$1,652 by 2025.

The data indicates that the overall Canadian cannabis market will grow by 50 percent to reach C$11 billion in 2025.

EY projects that the supply of cannabis will top demand within the next five years.

According to the firm, if this prediction comes true, the average cost of wholesale dried flower will decrease to between C$4 and C$5.

In February, The GrowthOp reported on the average price of dried marijuana for each province in Canada.

In arguing against the notion that increasing costs for legal marijuana products pushes consumers towards the illicit market, Zachary Pendley, EY Canada cannabis real estate and valuation leader, said the consumer trend is due to the slower-than-expected rollout for retail.

“As the industry matures, access to product eases and higher margin derivatives come online, we’ll see a rise in consumer spending on legal cannabis,” Pendley said in a press release.

On the road to the legalization of recreational marijuana in October 2018, provinces were tasked with setting up retail models.

However, the process wasn’t smooth for every area, with Ontario and BC conducting slower rollouts for the markets. Ontario is still set to open its privatized retail market starting April 1, with some shops opening their doors later.

The study also projects that, by the year 2025, 20 percent of the total adult population will be cannabis consumers.

In addition, it indicates how consumption trends for different types of products are set to change.

Consumption splits from EY show dried flower will command a leading 46-percent market share, with extracts securing 37-percent of the market by 2025.

Edibles will only obtain a 12-percent share, and non-edible derivatives placed last with a 5-percent market share. Both are scheduled to become legal in Canada on or before October 17, 2019.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities.

The presentation will be approximately 35 minutes, followed by a live question and answer session.

Keep reading... Show less

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”), reports that it has sold its 50% interest in Cobra Ventures Inc. (“Cobra”), which sale included all funds previously advanced by World Class to Cobra, to the remaining shareholder of Cobra, for $2,500,000 in cash

An investment group led by Richard Goldstein retains 100% control of Cobra, and its senior secured debenture of Hydrx Farms Ltd. (“Hydrx”), acquired by Cobra in October 2020.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Kurt Schmidt, President and Chief Executive Officer, will speak at the 24th Annual CIBC Western Institutional Investor Conference on Friday, January 22, 2021 at 4:10 p.m. EST.

A recording will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations .

Keep reading... Show less
  • Disease control of root-rot Aphanomyces zoospores in laboratory tests.
  • Outstanding Efficacy: 100% control at economic application rates within 24 hours.
  • Aphanomyces is a soil-borne root-rot disease that destroys peas, lentils, and legume crops.

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces”) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.

MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005322/en/

Keep reading... Show less